Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases
Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic...
- Autores:
- Tipo de recurso:
- Fecha de publicación:
- 2004
- Institución:
- Universidad del Rosario
- Repositorio:
- Repositorio EdocUR - U. Rosario
- Idioma:
- eng
- OAI Identifier:
- oai:repository.urosario.edu.co:10336/27119
- Acceso en línea:
- http://dx.doi.org/10.1136/ard.2004.029694
https://repository.urosario.edu.co/handle/10336/27119
- Palabra clave:
- Lupus erythematosus
systemic
Drug therapy
Rheumatic diseases
Sjogren's syndrome
- Rights
- License
- Abierto (Texto Completo)
id |
EDOCUR2_29ab6f58735b8735db1311db6567d5cb |
---|---|
oai_identifier_str |
oai:repository.urosario.edu.co:10336/27119 |
network_acronym_str |
EDOCUR2 |
network_name_str |
Repositorio EdocUR - U. Rosario |
repository_id_str |
|
spelling |
cf46f3e1-d879-434f-8edc-b92a80c6000214eeeeef-0dd9-4d97-ade8-3c4ea1314518b42918cf-d88a-4c7d-8420-36e1a7903e27363a398e-e9c8-42e8-bf3b-ad3017384726194747786002020-08-19T14:41:03Z2020-08-19T14:41:03Z2004-11-14Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjo¨gren’s syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis.application/pdfhttp://dx.doi.org/10.1136/ard.2004.029694ISSN: 0003-4967EISSN: 1468-2060https://repository.urosario.edu.co/handle/10336/27119engEuropean League Against RheumatismBMJ Publishing920No. 6913Annals of the Rheumatic DiseasesVol. 64Annals of the Rheumatic Diseases, ISSN: 0003-4967;EISSN: 1468-2060, Vol.64, No.6 (Jun 2005); pp. 913-920https://ard.bmj.com/content/annrheumdis/64/6/913.full.pdfAbierto (Texto Completo)http://purl.org/coar/access_right/c_abf2Annals of the Rheumatic Diseasesinstname:Universidad del Rosarioreponame:Repositorio Institucional EdocURLupus erythematosussystemicDrug therapyRheumatic diseasesSjogren's syndromeTolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseasesTolerancia y eficacia a corto plazo de rituximab en 43 pacientes con enfermedades autoinmunes sistémicasarticleArtículohttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501Gottenberg, J-EGuillevin, LLambotte, OCombe, BAnaya, Juan-Manuel10336/27119oai:repository.urosario.edu.co:10336/271192021-08-10 22:50:34.1https://repository.urosario.edu.coRepositorio institucional EdocURedocur@urosario.edu.co |
dc.title.spa.fl_str_mv |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
dc.title.TranslatedTitle.spa.fl_str_mv |
Tolerancia y eficacia a corto plazo de rituximab en 43 pacientes con enfermedades autoinmunes sistémicas |
title |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
spellingShingle |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases Lupus erythematosus systemic Drug therapy Rheumatic diseases Sjogren's syndrome |
title_short |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
title_full |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
title_fullStr |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
title_full_unstemmed |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
title_sort |
Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases |
dc.subject.keyword.spa.fl_str_mv |
Lupus erythematosus systemic Drug therapy Rheumatic diseases Sjogren's syndrome |
topic |
Lupus erythematosus systemic Drug therapy Rheumatic diseases Sjogren's syndrome |
description |
Objective: To assess the tolerance and efficacy of rituximab in patients with various autoimmune diseases seen in daily rheumatological practice. Methods: 866 rheumatology and internal medicine practitioners were contacted by email to obtain the files of patients treated with rituximab for systemic autoimmune diseases. Patients with lymphoma were analysed if the evolution of the autoimmune disease could be evaluated. Results: In all, 43 of 49 cases could be analysed, including 14 with rheumatoid arthritis (RA), 13 with systemic lupus erythematosus (SLE), six with primary Sjo¨gren’s syndrome (pSS), five with systemic vasculitis, and five with other autoimmune diseases. Rituximab was prescribed for lymphoma in two patients with RA and two with pSS. In the 39 other cases, rituximab was given because of the refractory character of the autoimmune disease. The mean follow up period was 8.3 months (range 2 to 26). There were 11 adverse events in 10 patients and treatment had to be discontinued in six. Efficacy was observed in 30 patients (70%): RA 11, SLE 9, pSS 5, vasculitis 2, antisynthetase syndromes 2, sarcoidosis 1. The mean decrease in corticosteroid intake was 9.5 mg/d (range 0 to 50) in responders. Seven patients experienced relapse after mean 8.1 months (5 to 15). Three patients died because of refractory autoimmune disease. Conclusions: Despite absence of marketing authorisation, rituximab is used to treat various refractory autoimmune diseases in daily rheumatological practice. This study showed good tolerance and short term clinical efficacy, with marked corticosteroid reduction in patients with SLE, pSS, vasculitis, and polymyositis. |
publishDate |
2004 |
dc.date.created.spa.fl_str_mv |
2004-11-14 |
dc.date.accessioned.none.fl_str_mv |
2020-08-19T14:41:03Z |
dc.date.available.none.fl_str_mv |
2020-08-19T14:41:03Z |
dc.type.eng.fl_str_mv |
article |
dc.type.coarversion.fl_str_mv |
http://purl.org/coar/version/c_970fb48d4fbd8a85 |
dc.type.coar.fl_str_mv |
http://purl.org/coar/resource_type/c_6501 |
dc.type.spa.spa.fl_str_mv |
Artículo |
dc.identifier.doi.none.fl_str_mv |
http://dx.doi.org/10.1136/ard.2004.029694 |
dc.identifier.issn.none.fl_str_mv |
ISSN: 0003-4967 EISSN: 1468-2060 |
dc.identifier.uri.none.fl_str_mv |
https://repository.urosario.edu.co/handle/10336/27119 |
url |
http://dx.doi.org/10.1136/ard.2004.029694 https://repository.urosario.edu.co/handle/10336/27119 |
identifier_str_mv |
ISSN: 0003-4967 EISSN: 1468-2060 |
dc.language.iso.spa.fl_str_mv |
eng |
language |
eng |
dc.relation.citationEndPage.none.fl_str_mv |
920 |
dc.relation.citationIssue.none.fl_str_mv |
No. 6 |
dc.relation.citationStartPage.none.fl_str_mv |
913 |
dc.relation.citationTitle.none.fl_str_mv |
Annals of the Rheumatic Diseases |
dc.relation.citationVolume.none.fl_str_mv |
Vol. 64 |
dc.relation.ispartof.spa.fl_str_mv |
Annals of the Rheumatic Diseases, ISSN: 0003-4967;EISSN: 1468-2060, Vol.64, No.6 (Jun 2005); pp. 913-920 |
dc.relation.uri.spa.fl_str_mv |
https://ard.bmj.com/content/annrheumdis/64/6/913.full.pdf |
dc.rights.coar.fl_str_mv |
http://purl.org/coar/access_right/c_abf2 |
dc.rights.acceso.spa.fl_str_mv |
Abierto (Texto Completo) |
rights_invalid_str_mv |
Abierto (Texto Completo) http://purl.org/coar/access_right/c_abf2 |
dc.format.mimetype.none.fl_str_mv |
application/pdf |
dc.publisher.spa.fl_str_mv |
European League Against Rheumatism BMJ Publishing |
dc.source.spa.fl_str_mv |
Annals of the Rheumatic Diseases |
institution |
Universidad del Rosario |
dc.source.instname.none.fl_str_mv |
instname:Universidad del Rosario |
dc.source.reponame.none.fl_str_mv |
reponame:Repositorio Institucional EdocUR |
repository.name.fl_str_mv |
Repositorio institucional EdocUR |
repository.mail.fl_str_mv |
edocur@urosario.edu.co |
_version_ |
1814167545607880704 |